These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 2313334

  • 21. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL, Hahn T.
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [Abstract] [Full Text] [Related]

  • 22. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Spinolo JA, Jagannath S, Velásquez W, Spitzer G, Cabanillas F, Hagemeister F, Horwitz LJ, Dicke KA.
    Leuk Lymphoma; 1993 Jan; 9(1-2):71-7. PubMed ID: 8477204
    [Abstract] [Full Text] [Related]

  • 23. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
    Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A.
    Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
    [Abstract] [Full Text] [Related]

  • 24. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
    Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI.
    J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722
    [Abstract] [Full Text] [Related]

  • 25. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F.
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [Abstract] [Full Text] [Related]

  • 26. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
    Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, Klingemann HG, Connors JM, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Fairey RN, O'Reilly SE, Phillips GL.
    Bone Marrow Transplant; 1999 Jun; 23(11):1131-8. PubMed ID: 10382952
    [Abstract] [Full Text] [Related]

  • 27. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT.
    J Clin Oncol; 2000 Dec 01; 18(23):3918-24. PubMed ID: 11099321
    [Abstract] [Full Text] [Related]

  • 28. Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.
    Yahalom J, Gulati S.
    Ann Oncol; 1991 Feb 01; 2 Suppl 2():67-71. PubMed ID: 2049322
    [Abstract] [Full Text] [Related]

  • 29. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb 01; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 30. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G.
    Blood; 1995 Mar 01; 85(5):1381-90. PubMed ID: 7858268
    [Abstract] [Full Text] [Related]

  • 31. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918
    [Abstract] [Full Text] [Related]

  • 32. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P, Gisselbrecht C, Ferme C, Lepage E, Baruchel A, Marolleau JP, Gerota O, Boiron M.
    Nouv Rev Fr Hematol (1978); 1991 May 01; 33(3):267-72. PubMed ID: 1956765
    [Abstract] [Full Text] [Related]

  • 33. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A, Kàtay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD.
    Ann Oncol; 1998 Mar 01; 9(3):289-95. PubMed ID: 9602263
    [Abstract] [Full Text] [Related]

  • 34. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival.
    Burns LJ, Daniels KA, McGlave PB, Miller WJ, Ramsay NK, Kersey JH, Weisdorf DJ.
    Bone Marrow Transplant; 1995 Jul 01; 16(1):13-8. PubMed ID: 7581112
    [Abstract] [Full Text] [Related]

  • 35. Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.
    Broun ER, Tricot G, Akard L, Nichols C, Cheerva A, Jansen J.
    Bone Marrow Transplant; 1990 May 01; 5(5):341-4. PubMed ID: 2190660
    [Abstract] [Full Text] [Related]

  • 36. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
    Rossi HA, Becker PS, Emmons RV, Westervelt P, Levy W, Liu Q, Clark Y, Ballen K.
    Bone Marrow Transplant; 2003 Mar 01; 31(6):441-6. PubMed ID: 12665838
    [Abstract] [Full Text] [Related]

  • 37. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
    Bone Marrow Transplant; 1997 Dec 01; 20(11):953-9. PubMed ID: 9422474
    [Abstract] [Full Text] [Related]

  • 38. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
    Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH.
    J Clin Oncol; 1995 Mar 01; 13(3):588-95. PubMed ID: 7884420
    [Abstract] [Full Text] [Related]

  • 39. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G.
    Ann Intern Med; 1986 Feb 01; 104(2):163-8. PubMed ID: 3511811
    [Abstract] [Full Text] [Related]

  • 40. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
    Ann Hematol; 2002 Feb 01; 81(2):96-102. PubMed ID: 11907790
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.